user

High Burden of Deep-Seated Plexiform Neurofibromas (PN) in Children with Neurofibromatosis 1 (NF1): Image-Defined Risk Factors

被引：0
|
作者：
Kelaidi, C. [1 ]
Petrikkos, L. [1 ]
Tzotzola, V. S. [1 ]
Antoniadi, K. [1 ]
Gavra, M. [2 ]
Stefanaki, K. [3 ]
Polychronopoulou, S. [1 ]
机构：
[1] Aghia Sophia Childrens Hosp, Dept Pediat Hematol & Oncol, Athens, Greece
[2] Aghia Sophia Childrens Hosp, Dept Radiol, Athens, Greece
[3] Aghia Sophia Childrens Hosp, Dept Pathol, Athens, Greece
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V395 SIOP1
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [21] Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
    Yuan, X-J.
    Zhang, X.
    Li, Q.
    Wang, Z.
    Li, C.
    Liu, Y.
    Ge, X.
    Zhao, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1599 - S1599
  • [22] Erratum to: Tumor burden evaluation in NF1 patients with plexiform neurofibromas in daily clinical practice
    L. Pratt
    D. Helfer
    L. Weizman
    B. Shofty
    S. Constantini
    L. Joskowicz
    D. Ben Bashat
    L. Ben-Sira
    Acta Neurochirurgica, 2015, 157 : 1091 - 1091
  • [23] Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas.
    Robertson, K. A.
    Bowers, D. C.
    Yang, F.
    Vik, T.
    Ho, C.
    Croop, J.
    Walsh, L. E.
    Hingtgen, C.
    Pradhan, K. R.
    Hutchins, G.
    Fletcher, J. W.
    Cohen, M.
    Edwards-Brown, M.
    Travers, J. B.
    Yu, M.
    Nalepa, G.
    Denne, S.
    Ingram, D.
    Clapp, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas
    Jackson, Sadhana
    Baker, Eva H.
    Gross, Andrea M.
    Whitcomb, Patricia
    Baldwin, Andrea
    Derdak, Joanne
    Tibery, Cecilia
    Desanto, Jennifer
    Carbonell, Amanda
    Yohay, Kaleb
    O'Sullivan, Geraldine
    Chen, Alice P.
    Widemann, Brigitte C.
    Dombi, Eva
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [25] Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Baldwin, Andrea
    Dombi, Eva
    Wolters, Pamela
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Fisher, Michael J.
    Kim, AeRang
    Weiss, Brian D.
    Paul, Scott M.
    Clapp, Wade
    Farrell, Kathleen
    Smith, Michaele
    Fontana, Joseph
    Brofferio, Alessandra
    Steinberg, Seth M.
    Doyle, Laurence A.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] The development of cutaneous neurofibromas is influenced by familial and local factors in patients with Neurofibromatosis 1 (NF1).
    Palmer, C
    Szudek, J
    Joe, H
    Riccardi, VM
    Friedman, JM
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 132 - 132
  • [27] TOLERABILITY OF THE MTOR INHIBITOR SIROLIMUS IN A PHASE II STUDY FOR NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMAS: A NEUROFIBROMATOSIS CONSORTIUM STUDY
    Weiss, B.
    Widemann, B. C.
    Cantor, A.
    Perentesis, J.
    Vinks, A.
    Ullrich, N.
    Gutmann, D.
    Korp, B.
    Packer, R.
    Fisher, M. J.
    NEURO-ONCOLOGY, 2010, 12 (06) : II85 - II85
  • [28] SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Gross, Andrea
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Blakeley, Jaishri
    Whitcomb, Patricia
    Holmblad, Marielle
    Maritin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm
    Glod, John
    Steinberg, Seth
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2018, 20 : 143 - 144
  • [29] SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Blakeley, Jaishri O'Neill
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm A.
    Glod, John
    Steinberg, Seth M.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).
    Hittson, Lauren
    Glod, John
    Amaya, Melissa
    Derdak, Joanne
    Widemann, Brigitte C.
    Kaplan, Rosandra N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345